# US 2023/0058102 A1 · Solid state forms of blarcamesine salts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058102 A1
- Document ID: US20230058102A1
- Status: Published application
- Kind: A1
- Application number: 17/796,704
- Filed: 2021-02-03
- Published: 2023-02-23
- Earliest claimed: 2020-02-04
- Assignees: Teva Pharmaceuticals International GmbH
- Applicants: Teva Pharmaceuticals International GmbH
- Inventors: Polina Lapido; Jenny Goldshtein
- Web page: https://patentgrep.com/patent/US20230058102A1

## CPC

- C07D 307/14: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07C 57/145: Maleic acid
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure encompasses a novel solid state form of Blarcamesine and salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

## Claims

### Claim 1

A crystalline form of Blarcamesine HBr designated Form A, which is characterized by data selected from one or more of the following:
(a) an XRPD pattern having peaks at 6.4, 13.9, 19.2, 20.3 and 21.5 degrees 2-theta ± 0.2 degrees 2-theta;
(b) an XRPD pattern substantially as depicted in Figure 1;
(c) an XRPD pattern having peaks at 6.4, 13.9, 19.2, 20.3 and 21.5 degrees 2-theta ± 0.2 degrees 2-theta, and also having one, two, three, four or five additional peaks selected from 11.6, 13.1, 16.1, 22.3or 23.2 degrees two theta ± 0.2 degrees two theta;
(d) an X-ray powder diffraction pattern having peaks at 6.4, 11.6, 13.1, 13.9, 16.1, 19.2, 20.3, 21.5, 22.3 and 23.2 degrees 2-theta ± 0.2 degrees 2-theta;
(e) an X-ray powder diffraction pattern having peaks at 6.4, 11.6, 12.6, 13.1, 13.9, 16.1, 19.2, 20.3, 21.5, 22.3, 23.2, 25.4, 26.0, 27.5 and 29.0 degrees 2-theta ± 0.2 degrees 2-theta;
(f) a solid state 13C NMR spectrum with characteristic peaks at 143.7, 127.1, 59.0, 50.7 and 43.5 ppm ± 0.2 ppm;
(g) a solid state 13C NMR spectrum having the following chemical shift absolute differences from reference peak at 146.7 ppm ± 1 ppm: 3.0, 19.6, 87.7, 96.0 and 103.2 ppm ± 0.1 ppm;
(h) a solid state 13C NMR spectrum substantially as depicted in Figures 3, 4 or 5; and
(i) combinations of these data.

### Claim 2 (depends on 1)

The crystalline form according to claim 1, designated Form A, wherein the crystalline form is an anhydrous form.

### Claim 3 (depends on 1)

The crystalline form according to claim 1 , designated Form A, which contains no more than about 20% of any other crystalline forms of Blarcamesine HBr.

### Claim 4 (depends on 1)

The crystalline form according to claim 1, designated Form A, which contains no more than about 20% of amorphous Blarcamesine HBr.

### Claim 5

A crystalline form of Blarcamesine HBr designated Form B, which is characterized by data selected from one or more of the following:
(a) an XRPD pattern having peaks at 7.9, 10.2, 11.9, 15.9 and 21.1 degrees 2-theta ± 0.2 degrees 2-theta;
(b) an XRPD pattern substantially as depicted in Figure 7;
(c) an XRPD pattern having peaks at 7.9, 10.2, 11.9, 15.9 and 21.1 degrees 2-theta ± 0.2 degrees 2-theta, and also having one, two, three, four or five additional peaks selected from 13.1, 16.9, 17.9, 20.4 or 23.8 degrees two theta ± 0.2 degrees two theta;
(d) an X-ray powder diffraction pattern having peaks at 7.9, 10.2, 11.9, 13.1, 15.9, 16.9, 17.9, 20.4, 21.1 and 23.8 degrees 2-theta ± 0.2 degrees 2-theta;
(e) an X-ray powder diffraction pattern having peaks at 7.9, 10.2, 11.9, 13.1, 15.9, 16.4, 16.9, 17.9, 19.6, 20.0, 20.4, 21.1, 23.8, 24.3, 25.2, 25.5 and 26.3 degrees 2-theta ± 0.2 degrees 2-theta;
(f) a solid state 13C NMR spectrum with characteristic peaks at 144.8, 134.8, 47.0, 46.5 and 42.7 ppm ± 0.2 ppm;
(g) a solid state 13C NMR spectrum having the following chemical shift absolute differences from reference peak at 148.9 ppm ± 1 ppm: 4.1, 14.1, 101.9, 102.4 and 106.2 ppm ± 0.1 ppm;
(h) a solid state 13C NMR spectrum substantially as depicted in Figure 9, 10 or 11; and
(i) combinations of these data.

### Claim 6 (depends on 5)

The crystalline form according to claim 5, designated Form B, wherein the crystalline form is an anhydrous form.

### Claim 7 (depends on 5)

The crystalline form according to claim 5, designated Form B, which contains no more than about 20% of any other crystalline forms of Blarcamesine HBr.

### Claim 8 (depends on 5)

The crystalline form according to claim 5 , designated Form B, which contains no more than about 20% of amorphous Blarcamesine HBr.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A pharmaceutical composition comprising the crystalline form according to claim 1 and at least one pharmaceutically acceptable excipient.

### Claim 19 (depends on 1)

A process for preparing a pharmaceutical composition comprising combining the crystalline form according to claim 1, with at least one pharmaceutically acceptable excipient.

### Claim 20 (depends on 1)

A medicament comprising the crystalline form according to claim 1 .

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A method of treating Neurodegenerative and Neurodevelopmental Diseases including Alzheimer’s disease, Parkinson’s disease, dementia and/or Rett syndrome, comprising administering a therapeutically effective amount of the crystalline form according to claim 1 to a subject in need of the treatment.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

A process for preparing a Blarcamesine salt or a solid state form thereof, comprising preparing crystalline form of claim 1, and converting it to another solid state form of Blarcamesine or another salt or a solid state form thereof.

### Claim 25 (depends on 5)

A pharmaceutical composition comprising the crystalline form according to claim 5 and at least one pharmaceutically acceptable excipient.

### Claim 26 (depends on 5)

A process for preparing a pharmaceutical composition comprising combining the crystalline form according to claim 5, with at least one pharmaceutically acceptable excipient.

### Claim 27 (depends on 5)

A medicament comprising the crystalline form according to claim 5.

### Claim 28 (depends on 5)

A method of treating Neurodegenerative and Neurodevelopmental Diseases including Alzheimer’s disease, Parkinson’s disease, dementia and/or Rett syndrome, comprising administering a therapeutically effective amount of the crystalline form according to claim 5, to a subject in need of the treatment.

### Claim 29 (depends on 5)

A process for preparing a Blarcamesine salt or a solid state form thereof, comprising preparing crystalline form of claim 5, and converting it to another solid state form of Blarcamesine or another salt or a solid state form thereof.
